Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit.
Kalaycio
Matt E
ME
Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. kalaycm@ccf.org
Kukreja
Manisha
M
Woolfrey
Ann E
AE
Szer
Jeffrey
J
Cortes
Jorge
J
Maziarz
Richard T
RT
Bolwell
Brian J
BJ
Buser
Andreas
A
Copelan
Edward
E
Gale
Robert Peter
RP
Gupta
Vikas
V
Maharaj
Dipnarine
D
Marks
David I
DI
Pavletic
Steven Z
SZ
Horowitz
Mary M
MM
Arora
Mukta
M
D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019172:Transplantation Conditioning